-
Federal judge finds Lindis patents unenforceable in leukemia drug dispute, Amgen dodges $50 million payment
Read more: Federal judge finds Lindis patents unenforceable in leukemia drug dispute, Amgen dodges $50 million paymentThe District of Delaware has found two patents asserted in a dispute between Lindis and Amgen over the latter’s leukaemia drug Blincyto “unenforceable due to inequitable conduct”, rendering a prior $50 million jury verdict against Amgen irrelevant.
-
ETRI files HEVC SEP lawsuit against Hisense with UPC shortly after suing Transsion over same patent
Read more: ETRI files HEVC SEP lawsuit against Hisense with UPC shortly after suing Transsion over same patentKorea’s ETRI is now enforcing the same HEVC patent against two different Chinese defendants: smartphone maker Transsion as well as TV maker Hisense.
-
UPC Roundup (1 week): CoA clarifies two key prerequisites to suspension of enforcement; deposit may be used to offset costs; new cases
Read more: UPC Roundup (1 week): CoA clarifies two key prerequisites to suspension of enforcement; deposit may be used to offset costs; new casesThis is a summary of developments in and around the Unified Patent Court (UPC) in the week since our August 10, 2025 UPC Roundup. 1. CoA 1.1 CoA overturns denial of PI based on different take on imminent infringement (Boehringer Ingelheim v. Zentiva) (link to detailed article) The CoA has overturned a Lisbon LD decision that…
-
Donald Trump Jr. owns 5% of patent monetizer Fintiv, his second patent investment to come to light this year (after SIM IP)
Read more: Donald Trump Jr. owns 5% of patent monetizer Fintiv, his second patent investment to come to light this year (after SIM IP)We were first to report on Mr. Trump’s investment in famous patent monetizer Erich Spangenberg’s SIM IP. It turns out he has invested in at least one other patent monetizer.
-
Here’s how Apple is bringing back pulse oxymetry in the U.S. with a workaround that keeps clear of Masimo’s ITC import ban patents
Read more: Here’s how Apple is bringing back pulse oxymetry in the U.S. with a workaround that keeps clear of Masimo’s ITC import ban patentsApple has made headway against Masimo with a clearance decision by U.S. Customs and Border Protection for a designaround.
-
Boehringer wins nintedanib PI against Zentiva as UPC CoA reverses Lisbon LD on when infringement is imminent, clarifies how to argue national law
Read more: Boehringer wins nintedanib PI against Zentiva as UPC CoA reverses Lisbon LD on when infringement is imminent, clarifies how to argue national lawContext: Three months ago, the Unified Patent Court’s (UPC) Lisbon Local Division (LD) denied an application for provisional measures (which in some other jurisdictions would be called a motion for a preliminary injunction (PI)) by Boehringer Ingelheim against Zentiva, holding that an infringement did not appear imminent (item 2 of our May 10, 2025 UPC…
-
UPC’s Hague LD clarifies reimbursement of costs when infringement claim and revocation counterclaim differ in scope
Read more: UPC’s Hague LD clarifies reimbursement of costs when infringement claim and revocation counterclaim differ in scopeThis decision by the Hague LD in a food waste management case centered on validity. The patent survived only in a form for which no infringement was claimed.
-
UPC judge orders record security of €4M for costs, flatly rejects insurance policy as collateral even if issued by EU-based insurer
Read more: UPC judge orders record security of €4M for costs, flatly rejects insurance policy as collateral even if issued by EU-based insurerJudge Pichlmaier of the UPC’s Munich LD has rejected an insurance policy as collateral for costs and ordered a plaintiff to provide a total of €4M (€2M per case).


